New results from a phase 1 trial (NCT05507827) show that combining Orca-T with donor-derived (allogeneic) CAR T-cell therapy may be a safe and highly effective treatment for high-risk B-cell acute lymphoblastic leukemia (B-ALL). Traditional CAR T therapy often does not produce long-lasting remissions and is frequently used as a bridge to transplant. Orca-T is a specially engineered donor graft designed to control the immune response, while donor CAR T cells may provide stronger and more durable anti-cancer activity.
After a median follow-up of 473 days, all 16 patients in the study were alive and in complete remission. There were no cases of severe graft-versus-host disease, no graft failures, and all patients became MRD-negative, meaning no detectable leukemia remained. CAR T cells persisted beyond 100 days in several patients, addressing a common weakness of donor-based therapies.
Most patients developed cytokine release syndrome, but all cases were mild and manageable. Researchers are continuing to study how this combination reshapes the immune system and whether it could become a new standard approach for other high-risk B-cell cancers.